Molecular targets for cancer therapy and prevention

Chest

Volumn 125, Issue 5 SUPPL., 2004, Pages 97S-101S

  Gazdar, Adi F ^a,b   Miyajima, Kuniharu ^a   Reddy, Jyotsna ^a   Sathyanarayana, Ubaradka G ^a   Shigematsu, Hisayuki ^a   Suzuki, Makoto ^a   Takahashi, Takao ^a   Shivapurkar, Narayan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE; RETINOID; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER CELL; CANCER INVASION; CANCER PREVENTION; CANCER THERAPY; COLORECTAL CANCER; CONFERENCE PAPER; DRUG MECHANISM; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; INHIBITION KINETICS; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 2442597820     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.5_suppl.97S-a     Document Type: Conference Paper

References (29)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37(suppl):4-66
2. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47
3. Jensen PB, Sehested M, Langer SW, et al. Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory. Cancer Treat Rev 1999; 25:377-386
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70
5. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002; 21:5462-5482
6. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-193
7. Sun SY, Wan H, Yue P, et al. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000; 275:17149-17153
8. Omenn GS. Chemoprevention of lung cancer is proving difficult and frustrating, requiring new approaches. J Natl Cancer Inst 2000; 92:959-960
9. Lam S, MacAulay C, leRiche JC, et al. Key issues in lung chemoprevention trials of new agents. In: Senn H-J, Morant R, eds. Recent results in cancer research. Berlin, Germany: Springer-Verlag, 2003; 183-195
10. Virmani AK, Wistuba II, Gazdar AF. Molecular abnormalities in lung cancer and their relationship to histological subtypes. In: Hirsch FR, ed. Lung cancer: recent developments in diagnosis and treatment. Copenhagen, Denmark: Bristol-Myers-Squibb, 1999; 39-56
11. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428
12. Esteller M, Guo M, Moreno V, et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002; 62:5902-5905
13. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology (Huntingt) 2001; 15:21-26
14. Kikuchi T, Itoh F, Toyota M, et al. Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer 2002; 97:272-277
15. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001
16. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000; 30:73-81
17. El-Bayoumy K, Iatropoulos M, Amin S, et al. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1- butanone: the impact of a high-fat diet. Cancer Res 1999; 59:1400-1403
18. Kozaki K, Koshikawa K, Tatematsu Y, et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001; 20:4228-4234
19. Virmani AK, Tsou JA, Siegmund KD, et al. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epideiniol Biomarkers Prev 2002; 11:291-297
20. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001; 20:133-143
21. Akhurst RJ. TGF-β antagonists: why suppress a tumor suppressor? J Clin Invest 2002; 109:1533-1536
22. Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell 2002; 1:213-215
23. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109:113-124
24. Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene 2002; 21:4351-4362
25. Wu C, Sun M, Liu L, et al. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306:1-12
26. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174
27. Michelson PH, Tigue M, Jones JC. Human bronchial epithelial cells secrete laminin 5, express hemidesmosomal proteins, and assemble hemidesmosomes. J Histochem Cytochem 2000; 48:535-544
28. Sathyanarayana UG, Toyooka S, Padar A, et al. Epigenetic inactivation of laminin-5-encoding genes in lung cancers. Clin Cancer Res 2003; 9:2665-2672
29. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-2392